Lauren A. Buckley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lauren A. Buckley has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adrienne Bruder
Department of Pediatrics, Neonatal‐Perinatal Medicine University of Michigan Ann Arbor Michigan USA
1 shared publication Briana Clifton
Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota
1 shared publicationConnor Demorest
Masonic Cancer Center Biostatistics Core, University of Minnesota
1 shared publication- Debra R. Kulhanek
Department of Pediatrics, Division of Neonatology, University of Minnesota Medical School, Minneapolis, MN 55454, USA
1 shared publication - Ellen C. Ingolfsland
Department of Pediatrics, Division of Neonatology, University of Minnesota Medical School, Minneapolis, USA
1 shared publication - Ellen W. Demerath
Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States
1 shared publication
Latest Publications
- Open Access
- 3 August 2025
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2540477
Betamethasone latency period and neonatal hypoglycemia in term infants
Infants exposed to antenatal betamethasone (BMZ) between 34.0 and 36.6 weeks gestational age (GA) have increased risk for neonatal hypoglycemia, a known cause of brain injury. While a shorter latency period between BMZ administration and delivery is associated with an increased risk of neonatal hypoglycemia in late preterm infants, the impact of the BMZ latency period on neonatal hypoglycemia in infants born at term (≥37 weeks) has not been previously characterized. Term infants without additional risk factors such as growth restriction or maternal diabetes are not routinely screened and may be at risk for unrecognized neonatal hypoglycemia. The purpose of this study was to determine whether the latency period from antenatal BMZ administration to delivery impacts the incidence of neonatal hypoglycemia in term infants. This retrospective cohort study analyzed maternal-infant dyads from the University of Minnesota Obstetric Measures database (January 2017-August 2023) who received BMZ during pregnancy and delivered at ≥37 weeks (N = 758). The primary outcome was incidence of early neonatal hypoglycemia, defined as a blood glucose level N = 597) prior to delivery. Secondary outcomes included incidence of severe neonatal hypoglycemia (blood glucose level p < .001). Maternal diabetes status did not differ between groups. The recent BMZ group had lower median GA at birth (37.1 vs. 38.4 weeks, p < .001) and lower birth weight (3.03 vs. 3.29 kg, p < .001). The percentage of neonates classified as small for GA or large for GA was similar between groups. Approximately 30% of the neonates had a documented glucose measurement within 48 h of birth. The incidence of early neonatal hypoglycemia, severe hypoglycemia, and treatment for hypoglycemia with dextrose gel or IV dextrose did not differ between infants exposed to recent BMZ vs. those exposed to remote BMZ. In this cohort of term infants, a shorter latency period between BMZ administration and delivery was not associated with increased incidence or treatment of hypoglycemia. However, the rate of hypoglycemia screening was low in both groups and rates of undiagnosed hypoglycemia in BMZ-exposed term neonates remain unknown. Prospective longitudinal studies aimed at characterizing the risk of hypoglycemia in term infants exposed to BMZ would be beneficial to inform hypoglycemia screening practices in BMZ-exposed neonates.
- 3 August 2025
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2540477
Open AccessBetamethasone latency period and neonatal hypoglycemia in term infants
Infants exposed to antenatal betamethasone (BMZ) between 34.0 and 36.6 weeks gestational age (GA) have increased risk for neonatal hypoglycemia, a known cause of brain injury. While a shorter latency period between BMZ administration and delivery is associated with an increased risk of neonatal hypoglycemia in late preterm infants, the impact of the BMZ latency period on neonatal hypoglycemia in infants born at term (≥37 weeks) has not been previously characterized. Term infants without additional risk factors such as growth restriction or maternal diabetes are not routinely screened and may be at risk for unrecognized neonatal hypoglycemia. The purpose of this study was to determine whether the latency period from antenatal BMZ administration to delivery impacts the incidence of neonatal hypoglycemia in term infants. This retrospective cohort study analyzed maternal-infant dyads from the University of Minnesota Obstetric Measures database (January 2017-August 2023) who received BMZ during pregnancy and delivered at ≥37 weeks (N = 758). The primary outcome was incidence of early neonatal hypoglycemia, defined as a blood glucose level N = 597) prior to delivery. Secondary outcomes included incidence of severe neonatal hypoglycemia (blood glucose level p < .001). Maternal diabetes status did not differ between groups. The recent BMZ group had lower median GA at birth (37.1 vs. 38.4 weeks, p < .001) and lower birth weight (3.03 vs. 3.29 kg, p < .001). The percentage of neonates classified as small for GA or large for GA was similar between groups. Approximately 30% of the neonates had a documented glucose measurement within 48 h of birth. The incidence of early neonatal hypoglycemia, severe hypoglycemia, and treatment for hypoglycemia with dextrose gel or IV dextrose did not differ between infants exposed to recent BMZ vs. those exposed to remote BMZ. In this cohort of term infants, a shorter latency period between BMZ administration and delivery was not associated with increased incidence or treatment of hypoglycemia. However, the rate of hypoglycemia screening was low in both groups and rates of undiagnosed hypoglycemia in BMZ-exposed term neonates remain unknown. Prospective longitudinal studies aimed at characterizing the risk of hypoglycemia in term infants exposed to BMZ would be beneficial to inform hypoglycemia screening practices in BMZ-exposed neonates.
- Open Access
Inflammation as a Sex-Specific Mediator in the Relationship between Maternal and Offspring Obesity in C57Bl/6J Mice
Maternal obesity is a well-established risk factor for offspring obesity development. The relationship between maternal and offspring obesity is mediated in part by developmental programming of offspring metabolic circuitry, including hypothalamic signaling. Dysregulated hypothalamic inflammation has also been linked to development of obesity. We utilized an established C57Bl/6J mouse model of high-fat, high-sugar diet induced maternal obesity to evaluate the effect of maternal obesity on systemic and hypothalamic TNF-α, IL-6, and IL-1β levels in neonatal and adult offspring. The offspring of dams with obesity demonstrated increased adiposity and decreased activity compared to control offspring. Maternal obesity was associated with decreased plasma TNF-α, IL-6 and IL-1β in adult female offspring and decreased plasma IL-6 in neonatal male offspring. Neonatal female offspring of obese dams had decreased TNF-α gene expression in the hypothalamus compared to control females, while neonatal and adult male offspring of obese dams had decreased IL-6 gene expression in the hypothalamus compared to control males. In summary, our results highlight important sex differences in the inflammatory phenotype of offspring exposed to maternal obesity. Sex-specific immunomodulatory mechanisms should be considered in future efforts to develop therapeutic interventions for obesity prevention and treatment.
Open AccessInflammation as a Sex-Specific Mediator in the Relationship between Maternal and Offspring Obesity in C57Bl/6J Mice
Maternal obesity is a well-established risk factor for offspring obesity development. The relationship between maternal and offspring obesity is mediated in part by developmental programming of offspring metabolic circuitry, including hypothalamic signaling. Dysregulated hypothalamic inflammation has also been linked to development of obesity. We utilized an established C57Bl/6J mouse model of high-fat, high-sugar diet induced maternal obesity to evaluate the effect of maternal obesity on systemic and hypothalamic TNF-α, IL-6, and IL-1β levels in neonatal and adult offspring. The offspring of dams with obesity demonstrated increased adiposity and decreased activity compared to control offspring. Maternal obesity was associated with decreased plasma TNF-α, IL-6 and IL-1β in adult female offspring and decreased plasma IL-6 in neonatal male offspring. Neonatal female offspring of obese dams had decreased TNF-α gene expression in the hypothalamus compared to control females, while neonatal and adult male offspring of obese dams had decreased IL-6 gene expression in the hypothalamus compared to control males. In summary, our results highlight important sex differences in the inflammatory phenotype of offspring exposed to maternal obesity. Sex-specific immunomodulatory mechanisms should be considered in future efforts to develop therapeutic interventions for obesity prevention and treatment.
- Open Access
Late Growth and Changes in Body Composition Influence Odds of Developing Retinopathy of Prematurity among Preterm Infants
Background: While postnatal growth in the first month of life is known to impact retinopathy of prematurity (ROP) risk, the impact of growth later in hospitalization, during critical times of retinal vascularization, remains unknown. The purpose of this study was to assess if postnatal growth and body composition during the second half of neonatal intensive care unit hospitalization were associated with severity of retinopathy of prematurity in very low birth weight preterm infants. Methods: Prospective observational pilot study of 83 infants born p < 0.05). Conclusions: Improved growth later in neonatal intensive care unit hospitalization and increased adiposity at term may reduce odds of severe retinopathy of prematurity.
Open AccessLate Growth and Changes in Body Composition Influence Odds of Developing Retinopathy of Prematurity among Preterm Infants
Background: While postnatal growth in the first month of life is known to impact retinopathy of prematurity (ROP) risk, the impact of growth later in hospitalization, during critical times of retinal vascularization, remains unknown. The purpose of this study was to assess if postnatal growth and body composition during the second half of neonatal intensive care unit hospitalization were associated with severity of retinopathy of prematurity in very low birth weight preterm infants. Methods: Prospective observational pilot study of 83 infants born p < 0.05). Conclusions: Improved growth later in neonatal intensive care unit hospitalization and increased adiposity at term may reduce odds of severe retinopathy of prematurity.